Skip to main content

27-10-2016 | Rheumatoid arthritis | Review | Article

Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers

Philip M. Brown, Arthur G. Pratt, John D. Isaacs


The treatment and outcomes of patients with rheumatoid arthritis (RA) have been transformed over the past two decades. Low disease activity and remission are now frequently achieved, and this success is largely the result of the evolution of treatment paradigms and the introduction of new therapeutic agents. Despite the rapid pace of change, the most commonly used drug in RA remains methotrexate, which is considered the anchor drug for this condition. In this Review, we describe the known pharmacokinetic properties and putative mechanisms of action of methotrexate. Consideration of the pharmacodynamic perspective could inform the development of biomarkers of responsiveness to methotrexate, enabling therapy to be targeted to specific groups of patients. Such biomarkers could revolutionize the management of RA.

Nat Rev Rheumatol 2016;12:731–742. doi:10.1038/nrrheum.2016.175


Please log in to get access to this content

Related topics